Impact of plasma protein binding on antimicrobial activity using time-killing curves

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 5, 2004, Pages 876-880

  Zeitlinger, M A ^a   Sauermann, R ^a   Traunmuller F ^a   Georgopoulos, A ^a   Muller M ^a   Joukhadar, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Fosfomycin; Moxifloxacin; Protein binding; Time killing curve

Indexed keywords

ALBUMIN; AMPICILLIN; BETA LACTAM; FOSFOMYCIN; MOXIFLOXACIN; OXACILLIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMA PROTEIN BINDING; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BLOOD PROTEINS; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; QUINOLINES; SERUM ALBUMIN;

EID: 8844219660     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh443     Document Type: Article

References (21)

1. Peterson, L. R. & Gerding, D. N. (1980). Influence of protein binding of antibiotics on serum pharmacokinetics and extravascular penetration: clinically useful concepts. Review of Infectious Diseases 2, 340-8.
2. Wong, B. K., Bruhin, P. J. & Lin, J. H. (1999). Dose-dependent plasma clearance of MK-826, a carbapenem antibiotic, arising from concentration-dependent plasma protein binding in rats and monkeys. Journal of Pharmaceutical Sciences 88, 277-80.
3. Stoeckel, K. (1981). Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. Chemotherapy 27, Suppl. 1, 42-6.
4. Boswell, F. J., Ashby, J. P., Andrews, J. M. et al. (2002). Effect of protein binding on the in vitro activity and pharmacodynamics of faropenem. Journal of Antimicrobial Chemotherapy 50, 525-32.
5. Kunin, C. M. (1966). Clinical pharmacology of the new penicillins. 1. The importance of serum protein binding in determining antimicrobial activity and concentration in serum. Clinical Pharmacology and Therapeutics 7, 166-79.
6. Craig, W. A. & Ebert, S. C. (1989). Protein binding and its significance in antibacterial therapy. Infectious Disease Clinics of North America 3, 407-14.
7. Van der Auwera, P. & Klastersky, J. (1990). Study of the influence of protein binding on serum bactericidal titres and killing rates in volunteers receiving ceftazidime, cefotaxime and ceftriaxone. Journal of Hospital Infection 15, Suppl. A, 23-34.
8. Leggett, J. E. & Craig, W. A. (1989). Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram-negative bacilli. Antimicrobial Agents and Chemotherapy 33 35-40.
9. Merrikin, D. J., Briant, J. & Rolinson, G. N. (1983). Effect of protein binding on antibiotic activity in vivo. Journal of Antimicrobial Chemotherapy 11, 233-8.
10. Jones, R. N. & Barry, A. L. (1987). Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum. Antimicrobial Agents and Chemotherapy 31, 818-20.
11. Bergogne-Berezin, E. (2002). Clinical role of protein binding of quinolones. Clinical Pharmacokinetics 41, 741-50.
12. National Committee for Clinical Laboratory Standards. (1992). Methods for Determining Bactericidal Activity of Antimicrobial Agents: Tentative Guideline M26-T. NCCLS, Villanova, PA, USA.
13. Mueller, M., de la Pena, A. & Derendorf, H. (2004). Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrobial Agents and Chemotherapy 48, 369-77.
14. National Committee for Clinical Laboratory Standards. (2002). Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement: NCCLS Document M100-S12. NCCLS, Wayne, PA, USA.
15. Bennett, J. V. & Kirby, W. M. (1965). A rapid, modified ultrafiltration method for determining serum protein binding and its application to new penicillins. Journal of Laboratory and Clinical Medicine 66, 721-32.
16. Ullmann, U. (1977). The binding of isoxazolyl penicillins to human serum proteins. Drug Research 27, 2136-8.
17. Woodcock, J. M., Andrews, J. M., Boswell, F. J. et al. (1997). In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 41, 101-6.
18. Kirby, W. M. (1977). Pharmacokinetics of fosfomycin. Chemotherapy 23, Suppl. 1, 141-51.
19. Kunin, C. M., Craig, W. A., Kornguth, M. et al. (1973). Influence of binding on the pharmacologic activity of antibiotics. Annals of the New York Academy of Sciences 226, 214-24.
20. Turnidge, J. (1999). Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58, Suppl. 2, 29-36.
21. Rubinstein, E., Diamantstein, L., Yoseph, G. et al. (2000). The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. Clinical Microbiology and Infection 6, 678-81.